Crucian Carp-Derived ACE-Inhibitory Peptides with In Vivo Antihypertensive Activity: Insights into Bioactivity, Mechanism, and Safety.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Crucian Carp-Derived ACE-Inhibitory Peptides with In Vivo Antihypertensive Activity: Insights into Bioactivity, Mechanism, and Safety.
- Published In:
- Molecules (Basel, Switzerland), 30(13) (2025)
- Authors:
- Han, Runxi, Tian, Jingshan, Han, Yingge, Wang, Guoxiang, Zhou, Guanghong, Dai, Chen, Wang, Chong
- Database ID:
- RPEP-11270
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11270APA
Han, Runxi; Tian, Jingshan; Han, Yingge; Wang, Guoxiang; Zhou, Guanghong; Dai, Chen; Wang, Chong. (2025). Crucian Carp-Derived ACE-Inhibitory Peptides with In Vivo Antihypertensive Activity: Insights into Bioactivity, Mechanism, and Safety.. Molecules (Basel, Switzerland), 30(13). https://doi.org/10.3390/molecules30132812
MLA
Han, Runxi, et al. "Crucian Carp-Derived ACE-Inhibitory Peptides with In Vivo Antihypertensive Activity: Insights into Bioactivity, Mechanism, and Safety.." Molecules (Basel, 2025. https://doi.org/10.3390/molecules30132812
RethinkPeptides
RethinkPeptides Research Database. "Crucian Carp-Derived ACE-Inhibitory Peptides with In Vivo An..." RPEP-11270. Retrieved from https://rethinkpeptides.com/research/han-2025-crucian-carpderived-aceinhibitory-peptides
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.